Economic information and modeling report
Budget impact model
17 evidence topics · 12 sources
Atebrioz (zilurgisertib)
Fibrodysplasia ossificans progressiva
- Manufacturer
- Mirum Pharmaceuticals
- Regulatory submission
- NDA submitted by May 2026
- Last updated